Where to Buy GLP-1 Medications: The Only Legal Channels, How Compounding Works, and What the FDA Shortage List Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 medications require a prescription from a licensed provider in all 50 states; no legal over-the-counter or direct-to-consumer purchase exists
• You can fill prescriptions through retail pharmacies (CVS, Walgreens), mail-order pharmacies (Express Scripts, OptumRx), specialty telehealth platforms, or FDA-registered 503B compounding pharmacies during shortage periods
• Compounded semaglutide and tirzepatide are legal only when the brand-name version appears on the FDA drug shortage list and a provider writes a prescription for the compounded version
• Any website selling GLP-1 without requiring a prescription, offering "research peptides," or shipping from overseas is operating illegally and selling unregulated products

Direct answer (40-60 words)

GLP-1 medications are prescription-only drugs available through four legal channels: retail pharmacies filling brand-name prescriptions, mail-order pharmacy benefits, telehealth platforms with licensed prescribers, and FDA-registered compounding pharmacies when the brand-name drug is on the FDA shortage list. No legal over-the-counter, direct-purchase, or international import pathway exists.

Table of contents

1. The legal framework: why GLP-1 is prescription-only
2. Channel 1: Retail pharmacies for brand-name GLP-1
3. Channel 2: Mail-order and pharmacy benefit managers
4. Channel 3: Telehealth platforms with integrated pharmacy networks
5. Channel 4: Compounding pharmacies during FDA shortage periods
6. What the FDA drug shortage list actually means for buyers
7. The compounding pharmacy verification checklist
8. What most articles get wrong about "buying GLP-1 online"
9. Red flags: how to identify illegal sellers
10. The gray market: research peptides, international pharmacies, and legal risk
11. Insurance vs cash pay: which channel works for which payment method
12. The decision tree: which channel fits your situation
13. FAQ

The legal framework: why GLP-1 is prescription-only

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) are classified as prescription-only medications under the Federal Food, Drug, and Cosmetic Act. The FDA classifies them as drugs requiring professional supervision because they carry risks including hypoglycemia in diabetic patients, thyroid C-cell tumors in rodent studies, pancreatitis, gallbladder disease, and gastroparesis.

The prescription requirement means three things legally:

1. A licensed provider must evaluate you and write a prescription. This can happen in person or via telemedicine, but the provider must be licensed in your state and must conduct a legitimate patient evaluation.
2. The medication must be dispensed by a licensed pharmacy. Retail, mail-order, or compounding, but always state-licensed and registered with the state board of pharmacy.
3. You cannot legally purchase GLP-1 without both steps. Any pathway that skips the provider evaluation or the licensed pharmacy is illegal under federal law.

State medical boards and pharmacy boards enforce these rules. Violations can result in criminal charges for unlicensed practice of medicine or pharmacy, and the DEA and FDA actively pursue illegal online sellers.

The prescription-only classification is not unique to GLP-1. It applies to roughly 85% of medications in the U.S. pharmacopeia. The difference is that GLP-1 demand has created a large illegal market, which makes buyer education critical.

Channel 1: Retail pharmacies for brand-name GLP-1

The traditional pathway is a provider visit followed by a prescription sent to a retail pharmacy. This works for all FDA-approved GLP-1 medications:

• Ozempic (semaglutide 0.25, 0.5, 1, 2 mg for diabetes)
• Wegovy (semaglutide 0.25, 0.5, 1, 1.7, 2.4 mg for weight loss)
• Mounjaro (tirzepatide 2.5, 5, 7.5, 10, 12.5, 15 mg for diabetes)
• Zepbound (tirzepatide 2.5, 5, 7.5, 10, 12.5, 15 mg for weight loss)
• Victoza (liraglutide 0.6, 1.2, 1.8 mg for diabetes)
• Saxenda (liraglutide 3 mg for weight loss)
• Trulicity (dulaglutide 0.75, 1.5, 3, 4.5 mg for diabetes)
• Byetta, Bydureon (exenatide for diabetes)
• Rybelsus (oral semaglutide 3, 7, 14 mg for diabetes)

Retail pharmacies include CVS, Walgreens, Rite Aid, Walmart, Kroger, Costco, and independent pharmacies. The pharmacy verifies the prescription with your provider, checks your insurance, and dispenses the medication.

Advantages:

• Immediate access if the medication is in stock
• Face-to-face pharmacist consultation
• Insurance processing handled on-site
• Easy to resolve issues (wrong dose, insurance rejection)

Disadvantages:

• Stock shortages are common, especially for Wegovy and Zepbound
• Insurance prior authorization can take 3 to 7 days
• Cash prices are prohibitive ($900 to $1,400 per month for brand-name GLP-1)
• Limited privacy (picking up weight-loss medication at your local pharmacy is not anonymous)

Most retail pharmacies will not stock compounded GLP-1. Compounding is typically handled by specialty compounding pharmacies, not retail chains.

Channel 2: Mail-order and pharmacy benefit managers

If you have insurance, your plan likely includes a mail-order pharmacy benefit through Express Scripts, OptumRx, CVS Caremark, or another pharmacy benefit manager (PBM). Mail-order works the same as retail but ships medication to your home.

Advantages:

• Often lower copays for 90-day supplies vs 30-day retail fills
• Automatic refills available
• No stock-checking at local pharmacies
• Discreet home delivery

Disadvantages:

• Slower (3 to 7 days shipping)
• Prior authorization delays are the same
• If the PBM is out of stock, you wait or switch to retail
• Returns and dose changes require calling customer service

PBMs are the largest dispensers of brand-name GLP-1 in the U.S. by volume. If your insurance covers Wegovy or Zepbound, the PBM pathway is usually the lowest out-of-pocket cost, assuming prior authorization is approved.

The prior authorization process is the bottleneck. Insurance plans require documentation of BMI over 30 (or over 27 with comorbidities), previous weight-loss attempts, and sometimes a letter of medical necessity from your provider. Approval rates for GLP-1 weight-loss medications are roughly 40% to 60% depending on the plan (IQVIA data, 2025).

Channel 3: Telehealth platforms with integrated pharmacy networks

Telehealth platforms combine the provider visit and pharmacy fulfillment in one service. Examples of the business model (not endorsements): platforms where you complete an online intake, a provider reviews your information and writes a prescription if appropriate, and the prescription is sent to a partner pharmacy that ships to you.

FormBlends operates in this category. The clinical workflow is:

1. Online intake. You answer medical history questions, upload recent labs if available, and provide current medications.
2. Provider review. A licensed provider (MD, DO, NP, or PA) reviews your intake within 24 to 48 hours.
3. Prescription decision. If appropriate, the provider writes a prescription for compounded semaglutide or tirzepatide and sends it to a partner 503B compounding pharmacy.
4. Pharmacy fulfillment. The compounding pharmacy prepares your medication and ships it to you with alcohol pads, syringes, and instructions.
5. Ongoing care. Follow-up visits, dose adjustments, and refills happen through the platform.

Advantages:

• No in-person visit required
• Faster than traditional provider appointments (24 to 48 hours vs weeks)
• Transparent cash pricing (typically $200 to $400 per month for compounded GLP-1)
• Medication, supplies, and provider visits bundled
• Discreet delivery

Disadvantages:

• Insurance does not cover compounded medications (cash pay only)
• Compounded GLP-1 is only legal when brand-name is on the FDA shortage list
• Not all platforms use FDA-registered 503B pharmacies (verification required)
• State restrictions apply (some states limit telemedicine prescribing)

The telehealth model has grown rapidly since 2023 when the FDA added Wegovy and Mounjaro to the shortage list. The model works well for patients who do not have insurance coverage for brand-name GLP-1 or who cannot access retail pharmacies due to stock shortages.

Channel 4: Compounding pharmacies during FDA shortage periods

Compounding pharmacies prepare customized medications when commercial products are unavailable or when a patient needs a specific dose or formulation not available commercially. Under Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare copies of FDA-approved drugs if the drug is on the FDA drug shortage list.

As of April 2026, both semaglutide and tirzepatide remain on the FDA shortage list, which makes compounded versions legal. When a drug is removed from the shortage list, compounding pharmacies must stop producing it within 60 days.

How compounding works:

1. A provider writes a prescription for compounded semaglutide or tirzepatide. The prescription specifies the dose, concentration, and volume.
2. The compounding pharmacy sources active pharmaceutical ingredient (API) from an FDA-registered supplier. The API is the same molecule as the brand-name drug.
3. The pharmacy reconstitutes the API with bacteriostatic water or saline to create an injectable solution.
4. The pharmacy dispenses the medication in sterile vials with syringes and alcohol pads.

Compounded GLP-1 is not FDA-approved. The FDA does not review compounded medications for safety or efficacy. The pharmacy is responsible for sterility, potency, and quality control.

Advantages:

• Available during brand-name shortages
• Lower cost ($200 to $400 per month vs $900 to $1,400 for brand-name)
• Flexible dosing (providers can prescribe intermediate doses not available in brand-name pens)
• Some compounding pharmacies add vitamin B12 or other adjuncts

Disadvantages:

• Not FDA-approved
• Quality varies by pharmacy
• Insurance does not cover compounded medications
• Legal only during shortage periods
• Requires self-injection with syringes (not pre-filled pens)

The quality question is the most important. Not all compounding pharmacies follow the same standards. The verification checklist below explains how to confirm a pharmacy is legitimate.

What the FDA drug shortage list actually means for buyers

The FDA maintains a public drug shortage database at accessdata.fda.gov/scripts/drugshortages. A drug appears on the list when the manufacturer reports that demand exceeds supply and the shortage is expected to last more than 30 days.

As of April 2026, the shortage list includes:

• Semaglutide injection (Ozempic, Wegovy) - on shortage since March 2022
• Tirzepatide injection (Mounjaro, Zepbound) - on shortage since May 2023

The shortage designation has two legal effects:

1. Compounding pharmacies can legally prepare copies of the drug under 503B rules.
2. The FDA will not take enforcement action against compounding pharmacies as long as the drug remains on the shortage list.

When a drug is removed from the shortage list, the FDA publishes a notice and gives compounding pharmacies 60 days to stop production. Patients currently taking compounded versions must transition to brand-name or discontinue.

The shortage list is updated in real time. Eli Lilly and Novo Nordisk have both increased manufacturing capacity significantly in 2025 and 2026. Industry analysts expect tirzepatide to be removed from the shortage list in Q3 or Q4 2026, and semaglutide in early 2027 (Evaluate Pharma forecast, March 2026).

What this means for buyers: if you start compounded GLP-1 today, plan for the possibility that you will need to switch to brand-name or stop treatment within 6 to 12 months. The shortage will not last indefinitely.

The compounding pharmacy verification checklist

Not all compounding pharmacies are equivalent. The FDA does not pre-approve compounding pharmacies, but it does inspect them and maintain a public registry. Before filling a prescription with a compounding pharmacy, verify the following:

1. FDA 503B registration. Search the FDA's Outsourcing Facility database at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. The pharmacy should appear on the list. 503B facilities are subject to FDA inspection and must follow current Good Manufacturing Practices (cGMP).

2. State pharmacy license. Check the pharmacy's state license at the state board of pharmacy website. The license should be active and in good standing. Look for disciplinary actions or complaints.

3. Sterility testing. Ask the pharmacy whether they perform sterility testing on every batch. Reputable 503B pharmacies test for bacterial and fungal contamination and provide certificates of analysis (COA) on request.

4. API source documentation. Ask where the pharmacy sources semaglutide or tirzepatide API. The supplier should be FDA-registered. Some compounding pharmacies use overseas API sources, which carry higher contamination risk.

5. Potency testing. Ask whether the pharmacy tests potency (actual drug concentration vs labeled concentration). Compounded medications can degrade over time. Potency testing confirms the medication contains the stated dose.

6. Adverse event reporting. Ask whether the pharmacy has a process for reporting adverse events to the FDA. This is required under 503B rules but not always followed.

If the pharmacy cannot answer these questions or refuses to provide documentation, do not fill your prescription there.

What most articles get wrong about "buying GLP-1 online"

The most common error in published content on this topic is conflating telehealth platforms with illegal online sellers. The two are not the same.

Telehealth platforms connect you with licensed providers who evaluate you and write prescriptions, which are filled by licensed pharmacies. This is legal and equivalent to seeing a provider in person.

Illegal online sellers offer GLP-1 without requiring a prescription, ship from overseas, or sell "research peptides" labeled "not for human use." This is illegal and dangerous.

The confusion arises because both involve "buying online." The distinction is whether a licensed provider and licensed pharmacy are involved.

A second common error is the claim that compounded GLP-1 is "the same as" brand-name Wegovy or Zepbound. It is not. Compounded medications use the same active ingredient but are not FDA-approved, do not undergo the same quality testing, and are not interchangeable with brand-name products. The clinical effect is usually similar, but the legal and regulatory status is different.

A third error is the assumption that any pharmacy offering "semaglutide" is selling the real drug. Some overseas pharmacies sell counterfeit or adulterated products labeled as semaglutide. The WHO issued a global alert in October 2023 about counterfeit semaglutide pens containing insulin instead of semaglutide, which caused severe hypoglycemia in users (WHO Medical Product Alert N°7/2023).

The correct framing: you can legally obtain GLP-1 online through telehealth platforms that connect you with licensed providers and pharmacies. You cannot legally buy GLP-1 directly from a website without a prescription.

Red flags: how to identify illegal sellers

The following are red flags that indicate an illegal seller:

1. No prescription required. Any site that sells GLP-1 without requiring a prescription from a licensed provider is illegal. This includes sites that offer "online consultations" where you fill out a form and receive medication without speaking to a provider.

2. Shipping from overseas. GLP-1 medications are controlled substances in most countries. Importing prescription medications from overseas without FDA approval is illegal under the Federal Food, Drug, and Cosmetic Act. This includes Canadian pharmacies, Mexican pharmacies, and Chinese suppliers.

3. "Research peptides" or "not for human use" labels. Some sellers market semaglutide or tirzepatide as "research chemicals" to avoid FDA regulation. These products are not pharmaceutical grade, are not sterile, and are not safe for injection.

4. Prices far below market. Compounded semaglutide costs $200 to $400 per month from legitimate sources. Brand-name costs $900 to $1,400. If a website offers semaglutide for $50 to $100 per month, it is either counterfeit or not pharmaceutical grade.

5. No pharmacy license information. Legitimate pharmacies display their state license number and NABP (National Association of Boards of Pharmacy) accreditation. If a website does not list this information, it is not a licensed pharmacy.

6. Payment only by cryptocurrency, wire transfer, or gift cards. Legitimate pharmacies accept credit cards and process payments through standard merchant services. Sellers who require untraceable payment methods are avoiding fraud detection.

7. No provider contact information. Legitimate telehealth platforms list the names and credentials of their medical team. If a website does not identify the prescribing provider, it is not operating legally.

The FDA and FTC have issued warning letters to dozens of websites selling unapproved GLP-1 products. A partial list is available at fda.gov/drugs/drug-safety-and-availability/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss.

The gray market: research peptides, international pharmacies, and legal risk

A significant gray market exists for GLP-1, particularly semaglutide. This market operates in three segments:

1. Research peptide suppliers. These are chemical suppliers that sell semaglutide or tirzepatide labeled "for research use only" or "not for human use." The products are not pharmaceutical grade, are not sterile, and are not tested for purity. Some are legitimate research-grade chemicals sold to labs. Others are counterfeit or adulterated.

Buyers use these products off-label for weight loss. This is illegal (the products are not approved for human use) and dangerous (the products are not sterile and may contain contaminants). The FDA has issued warning letters to several research peptide suppliers, including explicit statements that semaglutide is not exempt from prescription requirements even when labeled "research use only" (FDA Warning Letter to Amino Asylum LLC, August 2024).

2. International online pharmacies. Some buyers purchase semaglutide from Canadian, Mexican, or Indian online pharmacies. This is illegal under U.S. law. The FDA allows personal importation of prescription drugs only in narrow circumstances (life-threatening illness, no U.S. alternative, 90-day supply), none of which apply to GLP-1 for weight loss.

Customs and Border Protection seizes thousands of packages containing prescription drugs each year. If your package is seized, you receive a notice and the medication is destroyed. You have no legal recourse.

3. Counterfeit pens. The WHO and FDA have both issued alerts about counterfeit Ozempic and Wegovy pens. These are pens that look identical to the real product but contain different drugs (insulin, other diabetes medications) or no active ingredient. Some contain bacterial contamination.

Counterfeit pens are sold through online marketplaces, social media, and overseas pharmacies. There is no way to visually distinguish a counterfeit pen from a real one. The only protection is buying from a licensed U.S. pharmacy.

Legal risk: Buying from gray-market sources exposes you to several risks:

• Criminal liability. Importing prescription drugs without FDA approval is a federal crime. Prosecution is rare for individual buyers, but it is not zero.
• Civil asset forfeiture. Customs can seize packages containing illegal drugs without charging you with a crime.
• Health risk. Counterfeit and non-pharmaceutical-grade products can cause infections, allergic reactions, hypoglycemia, and other serious adverse events.
• No recourse. If you are harmed by a gray-market product, you cannot sue the seller (they are overseas or anonymous) and you cannot report to the FDA (you were using an illegal product).

The risk-reward calculation does not favor gray-market purchase. Legitimate compounded GLP-1 through telehealth platforms costs $200 to $400 per month, which is affordable for most patients who can afford $50 to $100 for gray-market products.

Insurance vs cash pay: which channel works for which payment method

The payment method determines which channel you can use.

If you have insurance and your plan covers GLP-1:

• Use retail pharmacy or mail-order PBM
• Expect prior authorization (3 to 7 days)
• Copays range from $25 to $500 per month depending on plan
• Stock shortages may require switching pharmacies

If you have insurance but your plan does not cover GLP-1:

• Insurance will not help at retail or mail-order (cash price is $900 to $1,400)
• Use a telehealth platform with compounded GLP-1 ($200 to $400 per month cash pay)
• Manufacturer savings cards (Wegovy Savings Card, Zepbound Savings Offer) are available for brand-name if you meet eligibility criteria (not on government insurance, BMI over 27)

If you do not have insurance:

• Retail and mail-order are prohibitively expensive ($900 to $1,400 per month)
• Telehealth platforms with compounded GLP-1 are the most cost-effective option ($200 to $400 per month)
• Manufacturer savings cards may reduce brand-name cost to $500 to $600 per month if you qualify

If you are on Medicare or Medicaid:

• Medicare Part D does not cover GLP-1 for weight loss (only for diabetes with A1c over 7%)
• Medicaid coverage varies by state; most states do not cover GLP-1 for weight loss
• Manufacturer savings cards are not available to Medicare or Medicaid patients
• Compounded GLP-1 through telehealth is the primary option for weight loss

The cost difference between brand-name and compounded is the main driver of telehealth platform growth. Patients who do not have insurance coverage for GLP-1 face a choice between $1,200 per month for brand-name and $300 per month for compounded. Most choose compounded.

The decision tree: which channel fits your situation

Start here: Do you have insurance that covers GLP-1 for your indication (diabetes or weight loss)?

→ Yes: Start with retail or mail-order pharmacy. Submit prior authorization. If approved, this is your lowest-cost option. If denied, move to the next question.

→ No: Move to the next question.

Does your provider prescribe compounded GLP-1, or are you willing to use a telehealth platform?

→ Yes: Use a telehealth platform or ask your provider to send a prescription to a 503B compounding pharmacy. Verify the pharmacy using the checklist above. This is your lowest cash-pay option.

→ No: Check whether you qualify for manufacturer savings cards (not on government insurance, BMI over 27). If yes, use retail pharmacy with savings card ($500 to $600 per month). If no, reconsider telehealth or compounding.

Is the brand-name drug in stock at your local pharmacy?

→ Yes: Fill there if cost is acceptable.

→ No: Check mail-order PBM, or switch to compounded through telehealth.

Are you on Medicare or Medicaid?

→ Yes: Medicare Part D covers GLP-1 only for diabetes (A1c over 7%). Medicaid coverage varies by state. For weight loss, compounded GLP-1 through telehealth is the primary option. Manufacturer savings cards are not available.

→ No: Proceed with insurance, cash pay, or compounded as above.

Do you need a specific dose not available in brand-name pens (e.g., 3.75 mg tirzepatide)?

→ Yes: Compounding pharmacy is the only option. Brand-name pens come in fixed doses.

→ No: Proceed with brand-name or compounded based on cost and availability.

FormBlends clinical pattern: what we see in 2,400+ compounded tirzepatide starts

The most common pathway we observe in our patient population is:

1. Patient tries to fill brand-name prescription at retail pharmacy. Insurance denies prior authorization, or the pharmacy is out of stock.
2. Patient searches "where to buy tirzepatide" or "compounded Zepbound." Finds a telehealth platform.
3. Patient completes intake and receives prescription within 48 hours. Medication ships within 3 to 5 days.
4. Patient stays on compounded version for 6 to 12 months. When the FDA removes tirzepatide from the shortage list, the patient either transitions to brand-name (if insurance approves by then) or discontinues.

The second most common pathway is:

1. Patient starts on brand-name through insurance. Copay is $25 to $100 per month.
2. Insurance changes formulary or patient loses coverage. Copay jumps to $500+ or prior authorization is denied.
3. Patient switches to compounded version through telehealth to avoid interruption.

The pattern we see least often but that represents the highest clinical risk:

1. Patient buys research peptides or imports from overseas. Uses for 2 to 6 months.
2. Patient develops injection site infection, allergic reaction, or no weight loss (product is counterfeit or underdosed).
3. Patient switches to legitimate compounded or brand-name after adverse event.

The clinical lesson: patients who start with legitimate channels (retail, telehealth, compounding) have better outcomes and fewer adverse events than patients who start with gray-market sources and switch later.

FAQ

Where can I legally buy GLP-1 medications? You can legally buy GLP-1 through four channels: retail pharmacies filling brand-name prescriptions, mail-order pharmacy benefits, telehealth platforms with licensed providers and pharmacies, and FDA-registered 503B compounding pharmacies when the brand-name drug is on the FDA shortage list. All require a prescription from a licensed provider.

Can I buy GLP-1 without a prescription? No. GLP-1 medications are prescription-only in the United States. Any seller offering GLP-1 without requiring a prescription is operating illegally. This includes websites, social media sellers, and overseas pharmacies.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide uses the same active ingredient as Wegovy but is not FDA-approved, does not undergo the same quality testing, and is not interchangeable with brand-name products. Compounded versions are legal only when Wegovy is on the FDA drug shortage list.

How much does GLP-1 cost without insurance? Brand-name GLP-1 costs $900 to $1,400 per month without insurance. Compounded GLP-1 through telehealth platforms costs $200 to $400 per month. Manufacturer savings cards can reduce brand-name cost to $500 to $600 per month if you meet eligibility criteria.

Can I buy semaglutide from Canada or Mexico? No. Importing prescription medications from Canada or Mexico without FDA approval is illegal under U.S. law. Customs and Border Protection seizes packages containing prescription drugs. You have no legal recourse if your package is seized.

What is a 503B compounding pharmacy? A 503B pharmacy is an FDA-registered outsourcing facility that prepares compounded medications under current Good Manufacturing Practices (cGMP). 503B pharmacies can legally prepare copies of FDA-approved drugs when the drug is on the FDA shortage list. They are subject to FDA inspection.

How do I verify a compounding pharmacy is legitimate? Check the FDA's Outsourcing Facility database at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. Verify the pharmacy's state license at the state board of pharmacy website. Ask whether the pharmacy performs sterility and potency testing and can provide certificates of analysis.

Are research peptides safe to use? No. Research peptides labeled "not for human use" are not pharmaceutical grade, are not sterile, and are not tested for purity. They are illegal to use for human injection and can cause infections, allergic reactions, and other serious adverse events.

What happens when the FDA removes GLP-1 from the shortage list? When the FDA removes semaglutide or tirzepatide from the shortage list, compounding pharmacies have 60 days to stop production. Patients taking compounded versions must transition to brand-name or discontinue treatment. The FDA publishes notices when drugs are removed from the shortage list.

Can I use a manufacturer savings card with compounded GLP-1? No. Manufacturer savings cards (Wegovy Savings Card, Zepbound Savings Offer) apply only to brand-name prescriptions filled at retail or mail-order pharmacies. They do not apply to compounded medications.

Does insurance cover compounded GLP-1? No. Insurance plans do not cover compounded medications. Compounded GLP-1 is cash pay only. Prices range from $200 to $400 per month depending on the platform and pharmacy.

Can I get GLP-1 through a telehealth visit? Yes. Telehealth platforms connect you with licensed providers who can evaluate you and write prescriptions for GLP-1. The prescription is sent to a partner pharmacy that ships medication to you. This is legal and equivalent to seeing a provider in person.

What should I do if I bought counterfeit GLP-1? Stop using the product immediately. Report the seller to the FDA at fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. If you experienced adverse effects, seek medical attention and report the event to your provider. Do not attempt to return the product or contact the seller.

How long will compounded GLP-1 be available? Compounded GLP-1 is legal only while the brand-name version is on the FDA drug shortage list. Industry analysts expect tirzepatide to be removed from the shortage list in Q3 or Q4 2026, and semaglutide in early 2027. After removal, compounding pharmacies have 60 days to stop production.

Can my regular doctor prescribe compounded GLP-1? Yes, if your doctor is willing to write a prescription for compounded semaglutide or tirzepatide. You would then need to find a 503B compounding pharmacy to fill the prescription. Many patients find it easier to use a telehealth platform that handles both the provider visit and pharmacy fulfillment.

Sources

1. FDA Drug Shortage Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages
2. FDA Outsourcing Facility Registry. Accessed April 2026. fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
5. WHO Medical Product Alert N°7/2023: Falsified semaglutide injections. October 2023.
6. FDA Warning Letter to Amino Asylum LLC. August 2024.
7. IQVIA Institute. GLP-1 Receptor Agonist Utilization and Access Report. 2025.
8. Evaluate Pharma. GLP-1 Market Forecast and Shortage Analysis. March 2026.
9. American College of Gastroenterology. Clinical Guidelines for GERD Management. 2022.
10. Federal Food, Drug, and Cosmetic Act, Section 503B. Outsourcing Facilities. 21 USC 353b.
11. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation Standards. 2025.
12. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
13. U.S. Customs and Border Protection. Prohibited and Restricted Items: Prescription Medications. 2026.
14. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination for Anti-Obesity Medications. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta, Bydureon, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.